SANOFI-AVENTIS (EPA:SAN) | WebDisclosure

Basculer en Français

11318	Companies
251472	Keywords
180590	Articles
137297	Press releases

Home
Companies
SANOFI-AVENTIS

PRESS RELEASE

published on 08/25/2025 at 18:30, 1 year 2 months ago

Sanofi: Disclosure of trading in own shares
BRIEF

published on 08/18/2025 at 18:35, 1 year 2 months ago

Sanofi Reports Total Shares and Voting Rights for July 2025

Voting Rights French Commercial Code Shares 2025 Sanofi
BRIEF

published on 08/18/2025 at 18:35, 1 year 2 months ago

Sanofi publie le nombre total d'actions et de droits de vote pour juillet 2025

Actions Droit De Vote 2025 Sanofi Code De Commerce Français
PRESS RELEASE

published on 08/18/2025 at 18:30, 1 year 2 months ago

Sanofi: Information concerning the total number of voting rights and shares - July 2025
Sanofi discloses total voting rights and issued shares as per French commercial and stock market regulations. Details available on their website

Voting Rights Shares French Regulations Investor Relations Sanofi
BRIEF

published on 08/14/2025 at 07:05, 1 year 2 months ago

Le rilzabrutinib de Sanofi obtient la désignation de médicament orphelin dans l’UE

Sanofi EMA Médicament Orphelin Rilzabrutinib Maladie IgG4
BRIEF

published on 08/14/2025 at 07:05, 1 year 2 months ago

Sanofi's rilzabrutinib granted orphan drug designation in the EU

Sanofi EMA Orphan Drug Rilzabrutinib IgG4 Disease
PRESS RELEASE

published on 08/14/2025 at 07:00, 1 year 2 months ago

Communiqué de presse : Le rilzabrutinib de Sanofi obtient la désignation de médicament orphelin dans l’UE pour la maladie liée aux IgG4
Sanofi obtient la désignation de médicament orphelin pour le rilzabrutinib dans l'UE contre la maladie liée aux IgG4. Étude de phase 2 positive présentée à l'EULAR 2025

États-Unis Sanofi Médicament Orphelin Rilzabrutinib Maladie IgG4
PRESS RELEASE

published on 08/14/2025 at 07:00, 1 year 2 months ago

Press Release: Sanofi’s rilzabrutinib earns orphan designation in the EU for IgG4-related disease
Sanofi’s rilzabrutinib granted orphan designation in EU for IgG4-related disease. Positive Phase 2 results presented at EULAR 2025 Congress showcasing efficacy and safety profile

Sanofi Rilzabrutinib Orphan Designation IgG4-related Disease EULAR 2025
PRESS RELEASE

published on 08/11/2025 at 18:30, 1 year 2 months ago

Sanofi: Disclosure of trading in own shares
BRIEF

published on 08/06/2025 at 07:05, 1 year 3 months ago

Sanofi Finalizes Acquisition of Vigil Neuroscience

Acquisition Sanofi Neurology Vigil Neuroscience VG-3927

Accesswire

Published on 11/11/2026 at 03:30, 6 hours 16 minutes ago

CoTec Holdings Corp. Files Third Quarter Financial Statements and MD&A and Provides Market Commentary
Published on 11/11/2026 at 00:40, 9 hours 6 minutes ago

Upgraded Tunkillia MRE Validates Optimised Scoping Study
Published on 11/10/2026 at 23:30, 10 hours 16 minutes ago

CCL Industries Announces 2026 Third Quarter Results
Published on 11/10/2026 at 23:00, 10 hours 46 minutes ago

Vanta Announces Appointment of Chief Financial Officer and Corporate Secretary
Published on 11/10/2026 at 23:00, 10 hours 46 minutes ago

Battery X Metals Announces Appointment of Chief Financial Officer and Corporate Secretary

View all ACCESSWIRE

EQS Group

Published on 11/11/2026 at 09:25, 21 minutes ago

DOBOT Unveils Three New Products at Its 2026 Robotics Ecosystem Conference
Published on 11/11/2026 at 09:05, 41 minutes ago

DeepL unveils Aure, its most lifelike Voice AI translation model yet
Published on 11/11/2026 at 09:00, 46 minutes ago

Holding(s) in Company
Published on 11/11/2026 at 09:00, 46 minutes ago

Municipality Finance issues a USD 50 million tap under its MTN programme
Published on 11/11/2026 at 09:00, 46 minutes ago

Original-Research: Multitude AG (von NuWays AG): BUY

Les Echos

Published on 11/10/2026 at 18:00, 15 hours 46 minutes ago

Déclaration du nombre total des droits de vote et du nombre d’actions au 31 octobre 2026
Published on 11/10/2026 at 17:45, 16 hours 1 minute ago

Damartex / Descriptif du programme de rachat d'actions
Published on 11/10/2026 at 17:40, 16 hours 6 minutes ago

Production du 3ième trimestre 2026
Published on 11/10/2026 at 17:35, 16 hours 11 minutes ago

ENGIE - Déclaration du nombre total d'actions et de droits de vote au 31 octobre 2026
Published on 11/10/2026 at 17:31, 16 hours 14 minutes ago

CNP Assurances SA annonce le succès de l’émission d’une obligation subordonnée Tier 2 de 500 M€.

View all LES ECHOS COMFI WIRE